Work

813MO Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.864

Authors: C. Hackenbruch, J.S. Heitmann, S. Jung, Y. Maringer, M. Wacker, A. Nelde, M. Marconato, L. Zieschang, C. Kammer, M.T. Özbek, M. Richter, M. Denk, H.R. Salih, J.S. Walz

Institutions: Deutsches Konsortium für Translationale Krebsforschung, Universitätsklinikum Tübingen

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402561401

FWCI: 0.289

Cites:

Cited by: 1

Related to: 10